Einmal Medigene bitte -- ungefähr soviel wie Medigene aktuell an Marktkapitalisierung insgesamt vorweisen kann, plant Lion Biotechnoligies durch die Ausgabe von 8 Millionen neuen Aktien zu 8 US-Dollar das Stück beim Börsenwechsel einzunehmen.
Risiko gilt natürlich (Auszug - bitte nachfolgenden Prospekt selbst lesen!): "... Potential competitors in the market for treating metastatic melanoma will be companies such as Bristol-Myers Squibb, Roche/Genentech, Merck, Amgen, Pfizer, and GlaxoSmithKline, which already have products on the market or in development. Other companies, such as Novartis, Celgene, Kite Pharmaceuticals, and Adaptimmune, which are focused on T cell therapies technologies to treat cancer, may also be competitors. All of these companies, and most of our other current and potential competitors have substantially greater research and development capabilities and financial, scientific, regulatory, manufacturing, marketing, sales, human resources, and experience than we do. Many of our competitors have several therapeutic products that have already been developed, approved and successfully commercialized, or are in the process of obtaining regulatory approval for their therapeutic products in the United States and internationally...." Meine Meinung - KEINE Handelsempfehlung. LBIO Lion Biotechnologies, Inc. (QB) Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) |
Thread abonnieren
